A Long-Acting Interleukin-7, rhIL-7-hyFc, Enhances CAR T Cell Expansion, Persistence, and Anti-tumor Activity

Investigators demonstrated that a long-acting form of recombinant human interleukin-7 fused with hybrid Fc (rhIL-7-hyFc) promoted proliferation, persistence, and cytotoxicity of human CAR T cells in xenogeneic mouse models and murine CAR T cells in syngeneic mouse models, resulting in long-term tumor-free survival.